Új besugárzási technikák a szolid tumorok kezelésében. Metasztázisok sugárterá piája

Orvosi Hetilap

Volumn 155, Issue 8, 2014, Pages 283-290

  Mayer, Árpád ^a   Póti, Zsuzsa ^a  

^a Fovárosi Onkoradiológiai Központ ^*  (Hungary)

Author keywords

metastases; novel radiotherapy techniques; solid tumours; stereotactic extracranial radiotherapy

Indexed keywords

METASTASES; METASZTÁZISOK; NOVEL RADIOTHERAPY TECHNIQUES; SOLID TUMOURS; STEREOTACTIC EXTRACRANIAL RADIOTHERAPY; SZOLID TUMOROK; SZTEREOTAXIÁS EXTRACRANIALIS SUGÁRTERÁPIA; ÚJ SUGÁRTERÁPIÁS TECHNIKÁK;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; CONE-BEAM COMPUTED TOMOGRAPHY; DOSE FRACTIONATION; EVIDENCE-BASED MEDICINE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASMS; PATIENT SELECTION; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED; SPINAL NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84894463253     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2014.29832     Document Type: Article

References (42)

1. Ngan, S. Y., Burmeister, B., Fisher, R. J., et al.: Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J. Clin. Oncol., 2012, 30 (31), 3827-3833.
2. Rödel, C., Klautke, G.: Lokale kontrolle bei T3 rektumkarzinomen. Strahlenther. Onkol., 2013, 189 (2), 166-167.
3. Prescribing, recording and reporting intensity modulated photon beam therapy (IMRT). ICRU report 83. Washington, 2010.
4. Otto, K.: Volumetric modulated arc therapy: IMRT in a single gantry arc. Med. Phys., 2008, 35 (1), 310-317.
5. Ling, C. C., Humm, J., Larson, S., et al.: Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int. J. Radiat. Oncol. Biol. Phys., 2000, 47 (3), 551-560.
6. Vrieze, O., Haustermans, K., De Wever, W., et al.: Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Radiother. Oncol., 2004, 73 (3), 269-275.
7. Fakhrian, K., Oechsner, M., Kampfer, S., et al.: Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk. Strahlenther. Onkol., 2013, 189 (4), 293-300.
8. Guckenberger, M., Goebel, J., Wilbert, J., et al.: Clinical outcome of dose-escalation image-giuded radiotherapy for spinal metastases. Int. J. Radiat. Oncol. Biol. Phys., 2009, 75 (3), 828-835.
9. Yang, D. S., Yoon, W. S., Chung, S. Y., et al.: Set-up uncertainty during breast radiotherapy. Strahlenther. Onkol., 2013, 189 (4), 315-320.
10. Langen, K. M., Jones, D. T.: Organ motion and its management. Int. J. Radiat. Oncol. Biol. Phys., 2001, 50 (1), 265-278.
11. Langsenlehner, T., Döller, C., Winkler, P., et al.: Impact of inter-and intrafraction deviations and residual set-up errors on PTV margins. Strahlenther. Onkol., 2013, 189 (4), 321-328.
12. Weichselbaum, R. R., Hellman, S.: Oligometastases revisited. Nat. Rev. Clin. Oncol., 2011, 8 (6), 378-382.
13. Rubin, P., Brasacchio, R., Katz, A.: Solitary metastases: Illusion versus reality. Semin. Radiat. Oncol., 2006, 16 (2), 120-130.
14. Onimaru, R., Shirato, H., Shimizu, S., et al.: Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int. J. Radiat. Oncol. Biol. Phys., 2003, 56 (1), 126-135.
15. Norihisa, Y., Nagata, Y., Takayama, K., et al.: Stereotactic body radiotherapy for oligometastatic lung tumors. Int. J. Radiat. Oncol. Biol. Phys., 2008, 72 (2), 398-403.
16. Nagata, Y., Wulf, J., Lax, I., et al.: Stereotactic radiotherapy of primary lung cancer and other targets: Results of consultant meeting of the International Atomic Energy Agency. Int. J. Radiat. Oncol. Biol. Phys., 2011, 79 (3), 660-669.
17. Niemierko, A., Goitein, M.: Modeling of normal tissue response to radiation: The critical volume model. Int. J. Radiat. Oncol. Biol. Phys., 1993, 25 (1), 135-145.
18. Park, C., Papiez, L., Zhang, S., et al.: Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 2008, 70 (3), 847-852.
19. Smolle-Juettner, F. M., Maier, A., Lindenmann, J., et al.: Resection in stage I/II non-small cell lung cancer. In: Heide, J., Schmittel, A., Kaiser, D., Hinkelbein, W. (eds.): Controversies in the treatment of lung cancer. Frontiers of Radiation Therapy and Oncology, Vol. 42. Karger, Basel, 2010, 71-77.
20. McGarry, R. C., Song, G., des Rosiers, P., et al.: Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest, 2002, 121 (4), 1155-1158.
21. Lanni, T. B. Jr., Grills, I. S., Kestin, L. L., et al.: Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer. Am. J. Clin. Oncol. 2011, 34 (5), 494-498.
22. Mehta, M., Manon, R.: Are more aggressive therapies able to improve treatment of locally advanced non-small cell lung cancer: combined modality treatment? Semin. Oncol., 2005, 32 (2 Suppl. 3), S25-S34.
23. Wulf, J., Baier, K., Mueller, G., et al.: Dose-response in stereotactic irradiation of lung tumors. Radiother. Oncol., 2005, 77 (1), 83-87.
24. Timmerman, R., Paulus, R., Galvin, J., et al.: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA, 2010, 303 (11), 1070-1076.
25. Timmerman, R., McGarry, R., Yiannoutsos, C., et al.: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J. Clin. Oncol., 2006, 24 (30), 4833-4839.
26. Onishi, H., Shirato, H., Nagata, Y., et al.: Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J. Thorac. Oncol., 2007, 2 (7 Suppl. 3), S94-S100.
27. Nagata, Y., Takayama, K., Matsuo, Y., et al.: Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int. J. Radiat. Oncol. Biol. Phys., 2005, 63 (5), 1427-1431.
28. Haasbeek, C. J., Lagerwaard, F. J., Slotman, B. J., et al.: Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J. Thorac. Oncol., 2011, 6 (12), 2036-2043.
29. Senthi, S., Haasbeek, C. J., Slotman, B. J., et al.: Outcomes of stereotactic ablative radiotherapy for central lung tumours: A systematic review. Radiother. Oncol., 2013, 106 (3), 276-282.
30. Yamashita, H., Nakagawa, K., Nakamura, N., et al.: Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat. Oncol., 2007, 2, 21.
31. Stephans, K. L., Djemil, T., Tendulkar, R. D., et al.: Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT). Int. J. Radiat. Oncol. Biol. Phys., 2012, 82 (2), 974-980.
32. Onishi, H., Shirato, H., Nagata, Y., et al.: Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int. J. Radiat. Oncol. Biol. Phys., 2011, 81 (5), 1352-1358.
33. Lagerwaard, F. J., Verstegen, N. E., Haasbeek, C. J., et al.: Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 2012, 83 (1), 348-353.
34. Inoue, T., Oh, R. J., Shiomi, H., et al.: Stereotactic body radiotherapy for pulmonary metastases. Prognostic factors and adverse respiratory events. Strahlenther. Onkol., 2013, 189 (4), 285-292.
35. Alongi, F., Arcangeli, S., Filippi, A. R., et al.: Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist, 2012, 17 (8), 1100-1107.
36. Siva, S., MacManus, M., Ball, D.: Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J. Thorac. Oncol., 2010, 5 (7), 1091-1099.
37. Borgelt, B. B., Gelber, R., Brady, L. W., et al.: The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. Int. J. Radiat. Oncol. Biol. Phys., 1981, 7 (5), 587-591.
38. Høyer, M., Swaminath, A., Bydder, S., et al.: Radiotherapy for liver metastases: a review of evidence. Int. J. Radiat. Oncol. Biol. Phys., 2012, 82 (3), 1047-1057.
39. Wang, P. M., Hsu, W. C., Chung, N. N., et al.: Radiotherapy with volumetric modulated arc therapy for hepatocellular carcinoma patients ineligible for surgery or ablative treatments. Strahlenther. Onkol., 2013, 189 (4), 301-307.
40. Sahgal, A., Bilsky, M., Chang, E. L., et al.: Stereotactic body radiotherapy for spinal metastases: current status with a focus on its application in the postoperative patient. J. Neurosurg. Spine, 2011, 14 (2), 151-166.
41. Stieler, F., Wolff, D., Bauer, L., et al.: Reirradiation of spinal column metastases. Strahlenther. Onkol., 2011, 187 (7), 406-415.
42. Pan, H., Simpson, D. R., Mell, L. K., et al.: A survey of stereotactic body radiotherapy use in the United States. Cancer, 2011, 117 (19), 4566-4572.